Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial

•The maximum-tolerated dose (MTD) of idarubicin was 20 mg after two chemolipiodolisation sessions. •Intra-arterial idarubicin_lipiodol was well tolerated. •Intra-arterial idarubicin_lipiodol showed encouraging responses and survival. •Health-related quality of life results confirmed the good safety results. Background & Aims Idarubicin shows high cytotoxicity against hepatocellular carcinoma (HCC) cells, a high hepatic extraction ratio, and high...